INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.900
-0.170 (-8.21%)
At close: Jul 17, 2026, 4:00 PM EDT
1.950
+0.050 (2.63%)
After-hours: Jul 17, 2026, 7:58 PM EDT
INmune Bio Employees
INmune Bio had 21 employees as of December 31, 2025. The number of employees decreased by 1 or -4.55% compared to the previous year.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
n/a
Profits / Employee
-$1,981,000
Market Cap
50.51M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -1 | -4.55% | 21 | 0 |
| Dec 31, 2024 | 22 | 5 | 29.41% | 13 | 9 |
| Dec 31, 2023 | 17 | 7 | 70.00% | 11 | 6 |
| Dec 31, 2022 | 10 | 0 | - | 10 | 0 |
| Dec 31, 2021 | 10 | 5 | 100.00% | 10 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seres Therapeutics | 66 |
| aTyr Pharma | 60 |
| BeyondSpring | 44 |
| Mereo BioPharma Group | 39 |
| eXoZymes | 32 |
| Filana Therapeutics | 20 |
| Instil Bio | 17 |
| Eloxx Pharmaceuticals | 10 |
INMB News
- 4 days ago - INmune Bio's XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study - GlobeNewsWire
- 10 days ago - INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC - GlobeNewsWire
- 18 days ago - INmune Bio advances CORDStrom platform patent application in the U.S. - TheFly
- 18 days ago - INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion - GlobeNewsWire
- 24 days ago - INmune Bio receives MHRA approval for Ebstrocel pediatric investigation plan - TheFly
- 24 days ago - INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™ - GlobeNewsWire
- 26 days ago - INmune Bio announces MHRA alignment in pre-MAA CORDStrom meeting - TheFly
- 26 days ago - INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB - GlobeNewsWire